In the latest March/April 2024 issue of PRIME Journal, a compelling article details the clinical study conducted by Drs. Jamel Fares, Carlos Vivas, Yaribel Chan, and Juan Contreras on Duraform®, a revolutionary long-lasting PCL dermal filler. The study provides insights into the effectiveness and safety of Duraform®, highlighting its role in the ever-growing demand for non-surgical facial and body rejuvenation methods.
With the increasing life expectancy, more individuals are seeking ways to maintain a youthful appearance. Dermal fillers have become a popular solution, effectively addressing issues like volume loss, wrinkles, and facial contour enhancement.
Duraform®: An Innovative Approach:
Developed by Laboratoire GlobalSkin France, Duraform® is a unique blend of polycaprolactone (PCL) and hyaluronic acid (HA), utilizing a new technology called ICH (INNOVATION CONCEPT HYBRID). This formulation not only fills but also stimulates collagen, promising long-lasting results and improved skin quality.
The study involved 200 patients, predominantly female, aged between 30 and 55 years. The trial spanned 720 days with multiple follow-up sessions, focusing on various facial and body applications including skin laxity, nasolabial folds, and even lipoatrophy in HIV patients.
Duraform® is applied using different injection techniques like linear threading, fanning, serial puncture, and bolus injections. The choice between needle or cannula is based on the practitioner’s preference, with the cannula method minimizing trauma and bruising.
The study reports an impressive 80% patient satisfaction rate, with individuals praising the long-lasting effects and enhanced skin quality. Only a small fraction (20%) did not meet their expectations. The results remained evident for more than two years post-treatment.
Duraform® has proven to be a safe and effective collagen stimulator, offering a new perspective in non-surgical skin rejuvenation. This study underscores its potential as a lasting solution for facial and body aesthetics, marking a significant advance in the field.
Duraform®’s success in the clinical trial reflects its potential to transform the approach to aesthetic medicine, offering patients a reliable, long-lasting solution for a more youthful appearance. Its unique properties and sustained results make it a game-changer in non-surgical rejuvenation.
Discover more about this innovative dermal filler in the March/April 2024 issue of PRIME Journal. https://issuu.com/im-aesthetics/docs/prime_jan_feb_2024
